HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Teräväinen, H. Articles by Hietanen, M. Search for Related Content PubMed PubMed Citation Articles by Teräväinen, H. Articles by Hietanen, M.

Initial treatment of parkinsonism with 8-alpha-amino-ergoline

Department of Neurology, University Central Hospital, Helsinki, Finland.

We treated 12 patients with Parkinson's disease with an 8-alpha-amino-ergoline derivative, CU 32–085. The daily dosage was increased slowly to 7 mg over 9 weeks, held constant for 8 weeks, then replaced by placebo for 4 weeks. We found statistically significant benefit over placebo or pretreatment disability. The effect was seen at daily dosages of 3 mg or more. Its magnitude was dose related. There was no further improvement on prolonged treatment with 7 mg daily. Side effects were mild and did not require interruption of treatment.

Address correspondence and reprint requests to Dr. Teräväinen, Department of Neurology, University Central Hospital, Haartmaninkatu 4, SF-00290 Helsinki 29, Finland.

Financial support was provided by Yrjö Jahnsson Foundation, Finland, and the Academy of Finland.

Accepted for publication April 24, 1984.